News and Announcements
Strong interim results of CAVATAK in Phase 2 Trial
- Published July 19, 2013 10:42AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19 July 2013, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) today announced strong interim results from its Phase 2 clinical trial of CAVATAK™ treatment in late stage melanoma patients.
The interim data shows solid progress towards achieving the primary endpoint of the study and stregthens the evidence of the tolerability of CAVATAK™ in late stage melanoma patients.
Earlier today, Dr Robert Andtbacka, the lead study investigator from the Huntsman Cancer Institute in the USA, presented on the safety and investigator assessed efficacy data from the first 35 patients in the CALM study at the 8th World Congress of Melanoma, Hamburg, Germany.
To read the full ASX announcement, please download the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
